100x faster scientific evidence synthesis
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
San Francisco-based AI/data-infrastructure startup formerly known as Zenbase AI Inc. The company now focuses on "evidence infrastructure for pharma" and an AI research agent for systematic literature reviews, screening, extraction, verification, and living evidence synthesis.
Primary product
Eva, an AI research agent for systematic literature reviews and evidence synthesis
Founded
2024
Headquarters
San Francisco, California, United States
Team size
1-10 employees
Industry
Data Infrastructure and Analytics
Sub-industry
Scientific evidence synthesis / AI research software
Offices
0 jobs at The Synthesis Company
Check back later for new openings
Business model
Investors
Public messaging emphasizes working closely with human reviewers, continuous learning, and a research-heavy, accuracy-first culture.
Compensation
No public compensation information found.
Pricing
Not publicly disclosed; appears to be custom B2B/enterprise and API-based pricing.
Differentiators
Technology
Customers
Competitors
ResearchGate preprint · Jan 2026
Preprint authored by 16 researchers across 11 institutions, including The Synthesis Company founders; reports AI-assisted systematic-review performance on 30,150 documents with 97.2% screening sensitivity, 96.84% specificity, 96.96% extraction accuracy, and 98-99% time reduction.
LinkedIn · Jan 2026
Cyrus Nouroozi announced the validation study release, highlighting 16 researchers across 11 institutions and the headline result of 97% accuracy with 98-99% time savings.
LinkedIn · Jan 2026
Company announcement of the validation study, citing 30,000+ examined data points and 97% accuracy across screening and extraction.
LinkedIn · Nov 2025
Company post discussing open-source scientific claim verification tooling and the broader LLM-for-evidence-synthesis space.
LinkedIn · Nov 2025
Company post summarizing a risk-of-bias evaluation study and noting moderate agreement between ChatGPT-4o and human Cochrane reviewers.